Uncovering the role of immunosuppressive dendritic cells in pancreatic cancer

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a debilitating disease that continues to have rising incidence and mortality rates. In 2018, it is estimated that nearly 56,000 individuals will be newly diagnosed with pancreatic cancer (1). Surgical resection remains the only possible curative measure as pancreatic cancer is notoriously resistant to systemic chemotherapy, has high rates of recurrence, and is associated with a 5-year survival rate of 8.5 (1).